Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 160

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial

Open access
Sonnenblick, Amir, Agbor-Tarh, Dominique, Bradbury, Ian, Di Cosimo, Serena, Azim, Hatem A., Fumagalli, Debora, Sarp, Severine, Wolff, Antonio C., Andersson, Michael, Kroep, Judith, Cufer, Tanja, Simon, Sergio D., Salman, Pamela, Toi, Masakazu, Harris, Lyndsay, Gralow, Julie, Keane, Maccon, Moreno-Aspitia, Alvaro, Piccart-Gebhart, Martine, de Azambuja, Evandro·2017·Journal of Clinical Oncology

Abstract

Purpose: Previous studies have suggested an association between metformin use and improved outcome in patients with diabetes and breast cancer. In the current study, we aimed to explore this association in human epidermal growth factor receptor 2 (HER2 ) –positive primary breast cancer in the context of a large, phase III adjuvant trial. Patients and Methods: The ALTTO trial randomly assigned patients with HER2-positive breast cancer to receive 1 year of either trastuzumab alone, lapatinib alone, their sequence, or their combination. In this substudy, we evaluated whether patients with diabetes at study entry—with or without metformin treatment—were associated with different disease-free survival (DFS), distant disease-free survival (DDFS), and overall survival (OS) compared with patients without diabetes. Results: A total of 8,381 patients were included in the current analysis: 7,935 patients (94.7%) had no history of diabetes at diagnosis, 186 patients (2.2%) had diabetes with no metformin treatment, and 260 patients (3.1%) were diabetic and had been treated with metformin. Median follow-up was 4.5 years (0.16 to 6.31 years), at which 1,205 (14.38%), 929 (11.08%), and 528 (6.3%) patients experienced DFS, DDFS, and OS events, respectively. Patients with diabetes who had not been treated with metformin experienced worse DFS (multivariable hazard ratio [HR], 1.40; 95% CI, 1.01 to 1.94; P = .043), DDFS (multivariable HR, 1.56; 95% CI, 1.10 to 2.22; P = .013), and OS (multivariable HR, 1.87; 95% CI, 1.23 to 2.85; P = .004). This effect was limited to hormone receptor–positive patients. Whereas insulin treatment was associated with a detrimental effect, metformin had a salutary effect in patients with diabetes who had HER2-positive and hormone receptor–positive breast cancer. Conclusion: Metformin may improve the worse prognosis that is associated with diabetes and insulin treatment, mainly in patients with primary HER2-positive and hormone receptor–positive breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.69.7722

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 160

Metadata

Authors
Sonnenblick, A., Agbor-Tarh, D., Bradbury, I., Di Cosimo, S., Azim, H. A., Fumagalli, D., Sarp, S., Wolff, A. C., Andersson, M., Kroep, J., Cufer, T., Simon, S. D., Salman, P., Toi, M., Harris, L., Gralow, J., Keane, M., Moreno-Aspitia, A., Piccart-Gebhart, M., & de Azambuja, E.
Venue
Journal of Clinical Oncology
Published
2017-05-01
Volume
35
Issue
13
Pages
1421-1429
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2601249191
Cited by
160
References
5
FWCI
6.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. https://app.cochat.ai/papers/10.1200/jco.2016.69.7722
The paper
Sonnenblick, A., Agbor-Tarh, D., Bradbury, I., Di Cosimo, S., Azim, H. A., Fumagalli, D., Sarp, S., Wolff, A. C., Andersson, M., Kroep, J., Cufer, T., Simon, S. D., Salman, P., Toi, M., Harris, L., Gralow, J., Keane, M., Moreno-Aspitia, A., Piccart-Gebhart, M., & de Azambuja, E. (2017). Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2–Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.69.7722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.